Unknown

Dataset Information

0

TAS-102, a novel antitumor agent: a review of the mechanism of action.


ABSTRACT: Inhibition of nucleoside metabolism is an important principle in cancer therapy as evidenced by the role of fluoropyrimidines, such as 5-fluorouracil (5-FU), and antifolates in the treatment of many cancers. TAS-102 is an oral combination therapy consisting of trifluridine (FTD), a thymidine-based nucleoside analog, plus tipiracil hydrochloride (TPI), a novel thymidine phosphorylase inhibitor that improves the bioavailability of FTD. TAS-102 has demonstrated efficacy in 5-FU-refractory patients based on a different mechanism of action and has been approved for the treatment of metastatic colorectal cancer in Japan. This review describes the mechanism of action of TAS-102, highlighting key differences between TAS-102 and 5-FU-based therapies. While both FTD and 5-FU inhibit thymidylate synthase (TS), a central enzyme in DNA synthesis, sufficient TS inhibition by FTD requires continuous infusion; therefore, it is not considered a clinically relevant mechanism with oral dosing. Instead, the primary cytotoxic mechanism with twice-daily oral dosing, the schedule used in TAS-102 clinical development, is DNA incorporation. FTD incorporation into DNA induces DNA dysfunction, including DNA strand breaks. Uracil-based analogs such as 5-FU may also be incorporated into DNA; however, they are immediately cleaved off by uracil-DNA glycosylases, reducing their ability to damage DNA. Moreover, the TPI component may enhance the durability of response to FTD. With its distinct mechanism of action and metabolism, TAS-102 is a promising treatment option for patients resistant to or intolerant of 5-FU-based fluoropyrimidines.

SUBMITTER: Lenz HJ 

PROVIDER: S-EPMC4624296 | biostudies-literature | 2015 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

TAS-102, a novel antitumor agent: a review of the mechanism of action.

Lenz Heinz-Josef HJ   Stintzing Sebastian S   Loupakis Fotios F  

Cancer treatment reviews 20150606 9


Inhibition of nucleoside metabolism is an important principle in cancer therapy as evidenced by the role of fluoropyrimidines, such as 5-fluorouracil (5-FU), and antifolates in the treatment of many cancers. TAS-102 is an oral combination therapy consisting of trifluridine (FTD), a thymidine-based nucleoside analog, plus tipiracil hydrochloride (TPI), a novel thymidine phosphorylase inhibitor that improves the bioavailability of FTD. TAS-102 has demonstrated efficacy in 5-FU-refractory patients  ...[more]

Similar Datasets

| S-EPMC8637322 | biostudies-literature
| S-EPMC10340604 | biostudies-literature
| S-EPMC4750688 | biostudies-literature
| S-EPMC10856454 | biostudies-literature
| S-EPMC7599669 | biostudies-literature
| S-EPMC3919795 | biostudies-literature
| S-EPMC4882359 | biostudies-literature
| S-EPMC3405214 | biostudies-other
| S-EPMC6002804 | biostudies-literature
| S-EPMC4768213 | biostudies-literature